CN113874400B - 抗Vβ17/抗CD123双特异性抗体 - Google Patents

抗Vβ17/抗CD123双特异性抗体 Download PDF

Info

Publication number
CN113874400B
CN113874400B CN202080034083.XA CN202080034083A CN113874400B CN 113874400 B CN113874400 B CN 113874400B CN 202080034083 A CN202080034083 A CN 202080034083A CN 113874400 B CN113874400 B CN 113874400B
Authority
CN
China
Prior art keywords
seq
binding fragment
antigen
antibody
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080034083.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113874400A (zh
Inventor
R·贾尼桑
I·S·格雷瓦尔
M·A·塞普尔维达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority to CN202510015884.6A priority Critical patent/CN119954959A/zh
Publication of CN113874400A publication Critical patent/CN113874400A/zh
Application granted granted Critical
Publication of CN113874400B publication Critical patent/CN113874400B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080034083.XA 2019-03-11 2020-03-11 抗Vβ17/抗CD123双特异性抗体 Active CN113874400B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510015884.6A CN119954959A (zh) 2019-03-11 2020-03-11 抗Vβ17/抗CD123双特异性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962816464P 2019-03-11 2019-03-11
US62/816,464 2019-03-11
PCT/IB2020/000342 WO2020183245A2 (en) 2019-03-11 2020-03-11 ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510015884.6A Division CN119954959A (zh) 2019-03-11 2020-03-11 抗Vβ17/抗CD123双特异性抗体

Publications (2)

Publication Number Publication Date
CN113874400A CN113874400A (zh) 2021-12-31
CN113874400B true CN113874400B (zh) 2025-02-07

Family

ID=71670296

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080034083.XA Active CN113874400B (zh) 2019-03-11 2020-03-11 抗Vβ17/抗CD123双特异性抗体
CN202510015884.6A Pending CN119954959A (zh) 2019-03-11 2020-03-11 抗Vβ17/抗CD123双特异性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510015884.6A Pending CN119954959A (zh) 2019-03-11 2020-03-11 抗Vβ17/抗CD123双特异性抗体

Country Status (12)

Country Link
US (2) US12264197B2 (https=)
EP (1) EP3937977A2 (https=)
JP (2) JP7566766B2 (https=)
KR (1) KR20210138033A (https=)
CN (2) CN113874400B (https=)
AU (1) AU2020235475A1 (https=)
BR (1) BR112021017801A2 (https=)
CA (1) CA3132916A1 (https=)
IL (1) IL286147A (https=)
MA (1) MA55305A (https=)
MX (1) MX2021010857A (https=)
WO (1) WO2020183245A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7566766B2 (ja) 2019-03-11 2024-10-15 ヤンセン バイオテツク，インコーポレーテツド 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4192481A4 (en) * 2020-08-10 2024-09-11 Janssen Biotech, Inc. MATERIALS AND METHODS FOR THE PRODUCTION OF VIRUS-SPECIFIC BIOMODIFIED LYMPHOCYTES
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
MX2023002948A (es) * 2020-09-11 2023-05-22 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadena beta.
KR20230084507A (ko) * 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도
TWI815194B (zh) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20250092134A1 (en) * 2021-11-01 2025-03-20 Janssen Biotech, Inc. Compositions and methods for the modulation of beta chain-mediated immunity
CA3251397A1 (en) * 2022-02-09 2023-08-17 Janssen Biotech, Inc. METHODS AND COMPOSITIONS COMPRISING COMPONENTS FOR BRINGING BISORPOSE VΒ17 T LYMPHOCYTES TO CONTACT WITH BIOMODIFIED VIRUS-SPECIFIC LYMPHOCYTES
WO2024166047A1 (en) * 2023-02-09 2024-08-15 Janssen Biotech, Inc. Anti-v beta 17/anti-cd123 bispecific antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013131001A1 (en) * 2012-03-02 2013-09-06 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN107074956A (zh) * 2014-09-05 2017-08-18 詹森药业有限公司 Cd123结合剂及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6413516B1 (en) 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
FR2681875A1 (fr) 1991-09-26 1993-04-02 Immunotech Sa Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
US6084087A (en) 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2014159531A1 (en) 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
AR104250A1 (es) 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
WO2018112407A1 (en) * 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
KR20200041834A (ko) 2017-06-01 2020-04-22 젠코어 인코포레이티드 Cd123 및 cd3에 결합하는 이중특이성 항체
CA3081539A1 (en) 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2595980B (en) 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
JP7566766B2 (ja) 2019-03-11 2024-10-15 ヤンセン バイオテツク，インコーポレーテツド 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
AU2020298324A1 (en) 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIGIT antibodies
US20210130440A1 (en) 2019-10-03 2021-05-06 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
KR20220147631A (ko) 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
MX2023002948A (es) 2020-09-11 2023-05-22 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadena beta.
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
KR20230084507A (ko) 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013131001A1 (en) * 2012-03-02 2013-09-06 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN107074956A (zh) * 2014-09-05 2017-08-18 詹森药业有限公司 Cd123结合剂及其用途

Also Published As

Publication number Publication date
JP2024170426A (ja) 2024-12-10
BR112021017801A2 (pt) 2022-01-18
WO2020183245A2 (en) 2020-09-17
US20220127359A1 (en) 2022-04-28
JP7566766B2 (ja) 2024-10-15
IL286147A (en) 2021-10-31
CN119954959A (zh) 2025-05-09
EP3937977A2 (en) 2022-01-19
US20250257132A1 (en) 2025-08-14
WO2020183245A3 (en) 2020-12-03
MA55305A (fr) 2022-01-19
CA3132916A1 (en) 2020-09-17
KR20210138033A (ko) 2021-11-18
MX2021010857A (es) 2021-12-15
AU2020235475A1 (en) 2021-09-30
CN113874400A (zh) 2021-12-31
US12264197B2 (en) 2025-04-01
JP2022523442A (ja) 2022-04-22

Similar Documents

Publication Publication Date Title
CN113874400B (zh) 抗Vβ17/抗CD123双特异性抗体
CN113966231B (zh) 用于调节t细胞介导的免疫力的材料和方法
AU2022223152A1 (en) Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
CN107074956A (zh) Cd123结合剂及其用途
KR20160029128A (ko) 이중특이적 cd3 및 cd19 항원 결합 구조체
CN116209681A (zh) 包含hla-g抗原结合结构域的蛋白质及其用途
KR20240067052A (ko) 항-ccr8 항체
US20240360229A1 (en) Multispecific antibodies and uses thereof
JP2024507937A (ja) Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体
TWI870382B (zh) 抗trem1抗體及相關方法
CN117715940A (zh) 抗trem-1抗体
RU2831786C2 (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К Vβ17/CD123
CN121127496A (zh) 抗Vβ17/抗CD123双特异性抗体
WO2026073840A1 (en) Antibodies that bind to cd3 and uses therefor
CN119698435A (zh) 抗ilt4抗体及其医药用途
CN117986371A (zh) 结合CD123和γ-δT细胞受体的抗体
CN118742566A (zh) 包含用于免疫应答的增强型多特异性结合剂的组合物
HK40083338A (en) Antibodies binding to b7h4

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant